Amgen (AMGN) has triggered the SPY Bullish scanner at $415.84 — a signal with a verified 52.4% win rate across 966 backtested entries and a median excess return of +0.37% vs. SPY over the following 20 trading days. This is not a hype-driven move: Reddit mentions stand at just 1 today, near baseline, meaning price action is doing the talking entirely on its own.
The Signal
The SPY Bullish scanner identifies stocks exhibiting relative resilience and positive momentum alignment during periods when the broader market is in a constructive posture. It is a systematic, rules-based filter — not a discretionary call.
Our backtest across 966 entries shows:
- Win rate (positive after 20 trading days): 52.4%
- Median excess return vs. SPY over 20 days: +0.37%
This is a modest-edge signal, not a slam dunk. It identifies conditions that have historically resolved slightly in the bulls' favor — the value is in systematic tracking and position sizing discipline, not in treating any single trigger as a guarantee. What makes AMGN's trigger notable is the confluence of technical, fundamental, and options-market evidence that aligns with the signal's logic.
The Setup
AMGN is not a breakout chase here — it is a consolidating base within an established uptrend, which is precisely the kind of environment this scanner is designed to identify. The 100-day trend is classified as a strong uptrend with a price gain of +25.4% over that window, and the stock is trading above its long-run mean with very strong relative strength on the 100-day frame.
The 20-day trend is also up (+10.7%), with the stock pressing near a well-defined resistance zone. Crucially, the trendline scanner has flagged a Converging Wedge — Bullish pattern with a support floor at $396.01 and pattern resistance at $426.59. These are the two levels that frame the current decision point.
At $415.84, AMGN is sitting above its 20-day SMA of $403.90 and its 50-day SMA of $412.50 — both now acting as trailing support. The 5-day trend is up +3.3% and approaching near-term resistance, suggesting a pause or test is possible before any further extension.
Amgen's underlying business lends credibility to the technical setup. The company generates approximately $39 billion in annual revenue, with analysts expecting +6% revenue growth this fiscal year and EPS of roughly $23.04 — up from $21.84 a year ago. The next-quarter revenue consensus sits at $10.05 billion (+5.2% year-over-year), driven by continued volume growth in its inflammation, oncology, and cardiovascular portfolios, including MariTide (obesity) pipeline optionality that remains a longer-term wildcard.
What the Options Market Says
Options positioning is one of the stronger pieces of corroborating evidence here. The options flow score stands at 68/100, with the flow signal classified as accumulation — meaning net order flow is skewing toward call-side positioning rather than hedging or outright put buying. The MACD signal on options flow is bullish.
The gamma wall structure supports a constructive range. Market makers are carrying the heaviest open interest at the $420 call wall (8,855 contracts) and the $380 put wall (9,529 contracts). This creates a dealer-positioning corridor between approximately $380 and $420 that is likely to act as a magnet for price in the near term — with $420 serving as resistance that needs to be absorbed before any sustained push higher, and $380 acting as a gravitational floor if selling pressure emerges.
With the stock currently at $415.84, it is pressing the upper end of that corridor. The gamma bias is classified as bullish, consistent with the accumulation flow reading. RSI sits at 55.2 — not overbought, leaving room for continuation without an immediate mean-reversion headwind.
Key Levels to Watch
| Level | Price | Significance |
|---|---|---|
| Pattern Resistance / Call Wall | $420.00 – $426.59 | Converging wedge top + heavy call OI; key ceiling to clear |
| 20-Day Resistance | $417.78 | Near-term trendline cap; first test underway |
| 50-Day SMA | $412.50 | First trailing support; holding above here is constructive |
| 20-Day SMA | $403.90 | Secondary support; a close below this weakens the setup |
| Pattern Support / Wedge Base | $396.01 | Converging wedge lower bound; key risk line |
| Put Wall | $380.00 | Dealer gamma floor; major support if $396 gives way |
| 100-Day Support | $249.78 | Long-run structural support (far from current price) |
What Would Invalidate It
This setup is predicated on AMGN holding its converging wedge support and the broader SPY constructive posture that triggered the signal. There are three specific tripwires that would invalidate the thesis: (1) A daily close below $396.01 would break the wedge base and shift the near-term structure from consolidation to distribution — treat this as the hard stop line. (2) A close below the 20-day SMA at $403.90 without a quick recapture would be an early warning signal worth watching, particularly if accompanied by elevated volume. (3) A deterioration in the broader SPY trend that reverses the market condition that triggered this signal in the first place — this is a SPY-correlated scanner, so a meaningful SPY rollover would reduce the historical edge underpinning the 52.4% win rate. Additionally, the Street consensus target sits at $395.25 (mean) — currently below the stock price — which means AMGN is trading ahead of average analyst expectations. Any downward revision cycle or clinical disappointment in the obesity/MariTide pipeline could reprice estimates and drag the stock back toward consensus.
Analyst Sentiment
Wall Street's posture on AMGN is best described as cautiously constructive. Of 34 analysts tracked, 4 are strong buy, 8 are buy, and 17 are hold — a distribution that leans neutral. The mean price target is $395.25, with a median of $405.00 and a high target of $500.00. At $415.84, AMGN is currently trading approximately 4.7% above the mean target, which is a modest headwind from a top-down Street perspective.
The brighter spot is revision momentum: over the past 30 days, analysts have posted 31 upward EPS revisions against 24 downward, a net of +7 — a signal that the Street is gradually raising numbers rather than cutting them. Full-year EPS consensus has edged up from $22.35 ninety days ago to $23.04 today.
Bottom Line
AMGN has triggered the SPY Bullish scanner at $415.84, sitting inside a bullish converging wedge with options flow accumulation, a gamma-bullish dealer book, and positive EPS revision momentum. The 52.4% win rate across 966 backtested entries represents a systematic edge — small but real. The trade framework is straightforward: if AMGN holds above $396.01 (wedge support) and the SPY backdrop remains constructive, the signal's historical positive resolution rate applies. A clean break above the call wall zone of $420–$427 would confirm bulls are absorbing resistance. A close below $396.01 invalidates the setup entirely. This is signal-tracking, not a price target — the data simply says the odds tilt slightly in the bulls' favor from here, and we are documenting that in advance.
This article was generated by Tradestie Alpha Assistant using live market data (scanner signals, backtested hit rates, options positioning, and fundamentals). Backtest statistics describe historical cohorts, not guarantees. It is for informational purposes only and is not financial advice. Do your own research before making investment decisions.